European regulators say Teva violated antitrust laws

E

uropean regulators say that Teva Pharmaceuticals and its Cephalon unit breached antitrust rules by agreeing to delay a cheaper generic version of the Provigil sleep-disorder pill from reaching consumers.

The findings, which are preliminary, refer to the same so-called pay-to-delay arrangement that, two years ago, prompted Teva to pay $1.2 billion to the U.S. Federal Trade Commission to settle allegations that the companies violated antitrust law.

 

Source; https://www.statnews.com/pharmalot/2017/07/17/european-regulators-say-teva-violated-antitrust-laws/

Leave a Reply